A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of biib021 administered orally in patients with advanced solid tumors

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 445-455

  Saif, Muhammad Wasif ^a   Takimoto, Chris ^b   Mita, Monica ^b   Banerji, Udai ^c   Lamanna, Nicole ^d   Castro, Januario ^e   O'Brien, Susan ^g   Stogard, Christopher ^f   Hoff, Daniel Von ^h  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BIOGEN   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIIB 021; CORTICOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EYE TOXICITY; FAINTNESS; FATIGUE; FEVER; HEADACHE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERHIDROSIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENINE; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOPSY; DRUG ADMINISTRATION SCHEDULE; FLUORODEOXYGLUCOSE F18; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTRACELLULAR SPACE; LEUKOCYTES, MONONUCLEAR; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECEPTOR, ERBB-2;

EID: 84892708984     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1257     Document Type: Article

References (31)

1. Young JC, Moarefi I, Hartl FU. Hsp90: A specialized but essential protein-folding tool. J Cell Biol 2001;154:267-73.
2. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino- 17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273-9.
3. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002;2:3-24.
4. Karapanagiotou EM, Syrigos K, Saif MW. Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs 2009;18:161-74.
5. ® intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res 1997;14:1835-7.
6. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. Guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
8. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, et al. 89Zr-bevacizumab PET of earlyantiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010;51:761-7.
9. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 2013;71:1345-55.
10. Grem JL, Morrison G, Guo XD,Agnew E, Takimoto CH, Thomas R, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
11. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2010;46:340-7.
12. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 2010;28:1520-6.
13. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
14. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 30-kinase-AKTdependent pathway. Cancer Res 2002;62:3132-7.
15. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008;14:8302-7.
16. Wu WC, Wu MH, Chang YC, Hsieh MC, Wu HJ, Cheng KC, et al. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells. Exp Eye Res 2010;91: 211-9.
17. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, et al. Firstin- human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013;19:3671-80.
18. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG). Ann N Y Acad Sci 2006;1086:21-34.
19. Shen HY, He JC, Wang Y, Huang QY, Chen JF. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 2005;280:39962-9.
20. Den RB, Lu B. Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol 2012;4:211-8.
21. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res 2001;51:637-46.
22. Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann W. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997;96:4343-8.
23. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol 2011;153:729-40.
24. Frebel K, Wiese S. Signalling molecules essential for neuronal survival and differentiation. Biochem Soc Trans 2006;34(Pt 6):1287-90.
25. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17:5132-9.
26. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009;12:81-9.
27. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000;96:2284-91.
28. Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008;3:e0001722.
29. Den RB, Lu B. Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol 2012;4:211-8.
30. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al. Cancer and Leukemia Group B. Circulating HER-2/ erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7:2703-11.
31. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64.